ABSTRACT
Objectives : 1. To compare the percentage of patients that reach target LDL-C goals with 10 mg Vs. 20 mg of atorvastatin as a starting dose. 2. To compare Health Related Quality of Life (HRQOL) in patients on 10 mg Vs. 20 mg of atorvastatin. Methods : A prospective, double blind, parallel groups, unicentric study of patients of dyslipidemia, randomized to receive atorvastatin 10 mg (n=75) or atorvastatin 20 mg (n=75) once daily for 12 weeks. Safety reporting of incidence of adverse events was done. Results : Significantly more number of patients (P<0.05) reached target LDL-C levels at the end of 12 weeks in the 20 mg group (77.27% in the high risk group, 100% in moderately high risk group and 100% in the moderate risk group) when compared to 10 mg group (32% in the high risk group, 75% in moderately high risk group and 83.33% in the moderate risk group). Increase in HRQOL at the end of 12 weeks was also significantly greater (P<0.001) in 20 mg group (27.89%) vs. 10 mg group (19.26%). Conclusions : Selecting the starting dose of atorvastatin according to the patients risk category (by using the Framingham’s algorithm for calculating cardiovascular risk) and the percentage reduction in LDL required, will result in greater success in achieving LDL goals and better quality of life.
ABSTRACT
Mulberry is known to have hypoglycemic, hypotensive and diuretic property. Andallu et al in 2001 have shown hypoglycemic, hypolipidemic and antioxidant activity of mulberry in comparative clinical trial with glibenclamide. Methods: Mild newly diagnosed patients of DM type 2, (having fasting blood sugar > 126 mg %) were randomized into 2 groups of 9 each .One of the groups received crude Mulberry (Morus Indica) leaves preparation of 1gm tds in capsule form and the other group received Glibenclamide 5 mg /day for a total study period of 30 days. Results: Within group (pre and post) analysis revealed, group receiving glibenclamide showed significant reduction in post meal blood sugar levels (p<0.05). Whereas group on Mulberry treatment demonstrated statistically significant decrease in fasting and post meal blood sugar levels (24.6% and 19.9% respectively; p<0.05), triglyceride (16.04%, p<0.05), VLDL (10.7%, p<0.05) and total cholesterol (10%, p<0.05) levels. This Mulberry wing also showed a decreasing trend in LDL and a rising trend in HDL levels, although statistically not significant. Mulberry group had more favourable effect on subjective symptoms eg, fatigability (90% vs 70%), sense of well-being (100% vs 60%) and cramps and leg pain (66.66% vs 42.9 %). Between group analysis (comparison for change in parameters). Both the groups did not show statistical difference when compared for change in parameters over one month. Conclusion: Mulberry (Morus Indica) has the potential to be useful in mild type 2 DM for its hypoglycemic and hypolipidemic action.